GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Z

Zydus Lifesciences ZYDUSLIFE.NS · INR

Health Care · NSE · 🇮🇳 India

Compare

1,215.90

+1.50%

Close of 9 Nov 2026, in INR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in INR, from our data supplier.

FY2026

Revenue

₹271.48bn

FY2017FY2026

Net income

₹50.40bn

FY2017FY2026

Free cash flow

−₹12.03bn

FY2017FY2026

Shareholders' equity

₹271.11bn

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue₹271.48bn₹232.41bn₹195.47bn₹172.37bn₹151.10bn₹144.03bn₹142.53bn₹131.66bn₹119.05bn₹93.77bn
Gross profit₹140.30bn₹167.03bn₹131.54bn₹107.67bn₹94.24bn₹94.60bn₹91.73bn₹83.08bn₹76.60bn₹58.68bn
Research and development₹22.73bn₹19.45bn₹13.13bn₹12.41bn₹10.46bn₹11.25bn₹10.99bn₹9.53bn₹8.69bn₹7.55bn
Operating income₹62.26bn₹96.04bn₹75.95bn₹57.61bn₹51.29bn₹52.10bn₹47.66bn₹45.23bn₹43.04bn₹30.36bn
Net income₹50.40bn₹45.26bn₹38.59bn₹19.60bn₹44.87bn₹21.34bn₹11.77bn₹18.49bn₹17.76bn₹14.88bn
Diluted earnings per share50.1444.9738.3519.3744.3320.8511.4918.0517.3514.54

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets₹524.07bn₹372.02bn₹292.81bn₹257.56bn₹277.95bn₹238.85bn₹236.87bn₹234.83bn₹180.65bn₹152.21bn
Cash and short-term investments₹71.92bn₹78.08bn₹13.58bn₹11.92bn₹35.05bn₹11.27bn₹13.40bn₹10.00bn₹17.92bn₹16.05bn
Total liabilities₹228.24bn₹108.43bn₹71.79bn₹60.68bn₹87.42bn₹89.55bn₹119.76bn₹118.04bn₹91.30bn₹81.05bn
Debt—₹32.13bn₹8.04bn₹11.95bn₹42.21bn₹46.08bn₹80.14bn₹78.99bn₹54.07bn₹52.07bn
Shareholders' equity₹271.11bn₹239.53bn₹198.29bn₹175.16bn₹170.00bn₹129.92bn₹103.76bn₹103.86bn₹87.44bn₹69.60bn
Shares outstanding1,005m1,006m1,006m1,012m1,012m1,023m1,024m1,024m1,023m1,023m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations₹21.91bn₹67.77bn₹31.96bn₹26.89bn₹21.04bn₹32.93bn₹25.05bn₹28.82bn₹9.19bn₹13.49bn
Capital spending−₹33.94bn−₹17.13bn−₹9.07bn−₹10.31bn−₹12.03bn−₹8.54bn−₹9.04bn−₹10.57bn−₹10.49bn−₹29.78bn
Free cash flow−₹12.03bn₹50.64bn₹22.90bn₹16.58bn₹9.02bn₹24.39bn₹16.01bn₹18.25bn−₹1.30bn−₹16.29bn
Dividends paid−₹11.06bn−₹3.02bn−₹6.21bn−₹2.67bn−₹3.72bn−₹15.0m−₹7.17bn−₹3.58bn−₹10.0m−₹3.27bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₹80.17bn₹75.87bn₹68.64bn₹61.23bn₹65.74bn₹65.28bn₹52.69bn₹52.37bn
Gross profit₹38.54bn₹38.63bn₹35.29bn₹30.97bn₹47.84bn₹46.30bn₹36.86bn₹37.66bn
Operating income₹13.18bn₹14.01bn₹12.92bn₹13.00bn₹37.79bn₹2.40bn₹27.39bn₹28.86bn
Net income₹9.40bn₹12.72bn₹10.42bn₹12.59bn₹14.67bn₹11.71bn₹10.23bn₹9.11bn
Diluted earnings per share9.3512.6610.3612.5114.5811.6410.179.05
Cash from operations———₹9.46bn————
Capital spending———−₹8.68bn————
Free cash flow———₹785.0m————
Total assets—₹524.07bn—₹468.97bn—₹372.02bn—₹314.46bn
Cash and short-term investments₹49.71bn₹71.92bn₹70.69bn₹70.69bn₹56.37bn₹78.08bn₹24.95bn₹24.95bn
Debt—₹118.28bn—₹28.26bn—₹31.81bn—₹1.59bn
Shareholders' equity₹295.82bn₹271.11bn₹280.90bn₹253.02bn₹263.58bn₹239.53bn₹241.55bn₹218.25bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue16.3%13.5%11.2%
Operating income2.6%3.6%5.9%
Net income37.0%18.8%10.1%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin61.0%62.7%63.0%63.4%
Operating margin31.4%33.5%33.9%34.1%
Net margin19.0%17.6%18.9%17.3%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings23.820.325.335.69.523.241.514.120.129.9
Price to sales4.44.05.04.02.83.43.42.03.04.7

Dividends and splits

Per share, in the currency the company pays

Paid for 26 years. Last went ex-dividend on 24 Jul 2026.

FY2027FY2026FY2025FY2024FY2023FY2022FY2020FY2019
Paid in the year1.0011.003.006.002.503.507.003.50
  • 5-for-1 split · 6 Oct 2015
  • 3-for-2 split · 5 Apr 2010
  • 2-for-1 split · 30 Aug 2006

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.